3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Endometrial Neoplasms
6
Lymphatic Metastasis
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Clinical Stage I Gastric Cancer AJCC v8
2
Carcinoma, Transitional Cell
2
Vulvar Neoplasms
1
Urologic Neoplasms
1
Ureteral Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Postoperative Complications
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Mixed Tumor, Mesodermal
1
Melanoma
1
Lymphedema
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease
1
Cholangiocarcinoma
1
Interventions
Cisplatin
115
Radiotherapy
83
Paclitaxel
77
Fluorouracil
61
Carboplatin
41
Drug Therapy
34
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
toripalimab
23
Oxaliplatin
23
Neoadjuvant Therapy
23
Radiation
20
sintilimab
19
camrelizumab
19
130-nm albumin-bound paclitaxel
18
Esophagectomy
17
Capecitabine
17
Surgical Procedures, Operative
15
Leucovorin
15
Nivolumab
14
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
anlotinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Squamous Cell Carcinoma
×
Lymph Node Excision
×
Clear all
NCT07519486
2026-04-15
INS-ESCC-CT
Sichuan University
Phase 2
Recruiting
118 enrolled